Karyopharm Therapeutics Financials
Summary - Funding Rounds
Founding Date | 2008 |
Total Funding | $248.7 m |
Investors | Delphi Ventures, New Leaf Venture Partners, Foresite Capital |
Karyopharm Therapeutics is a subsidiary of Biogen
Revenue/Financials
Income Statement
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 387 k | 229 k | 250 k | |
Revenue growth, % | (41%) | 9% | ||
R&D expense | 28.5 m | 60.1 m | 97.7 m | 86.9 m |
General and administrative expense | 5.9 m | 15.9 m | 21.6 m | 23.9 m |
Operating expense total | 34.3 m | 76.1 m | 119.3 m | 110.9 m |
EBIT | (34 m) | (75.8 m) | (119.1 m) | (110.7 m) |
EBIT margin, % | (8773%) | (33121%) | (47630%) | |
Interest expense | 1 k | 1 k | ||
Interest income | 3 k | 97 k | 897 k | 1.3 m |
Pre tax profit | (109.4 m) | |||
Income tax expense | (139 k) | |||
Net Income | (33.9 m) | (75.8 m) | (118.2 m) | (109.6 m) |
- Source: SEC Filings
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
R&D expense | 11 m | 13.2 m | 16 m | 20.8 m | 27 m | 25.9 m | 21.8 m | 24.6 m | 19.9 m | 24.1 m | 23.1 m | 25.2 m |
General and administrative expense | 2.9 m | 3.3 m | 3.8 m | 5.4 m | 6.2 m | 4.8 m | 5.6 m | 6 m | 5.9 m | 6.3 m | 6.6 m | 5.8 m |
Operating expense total | 13.9 m | 16.5 m | 19.8 m | 26.2 m | 33.2 m | 30.7 m | 27.3 m | 30.5 m | 25.8 m | 30.3 m | 29.8 m | 31.1 m |
EBIT | (13.7 m) | (16.4 m) | (19.7 m) | (26.2 m) | (33 m) | (30.6 m) | (27.3 m) | (30.5 m) | (25.7 m) | (30.3 m) | (29.8 m) | (31.1 m) |
Interest expense | 18 k | |||||||||||
Interest income | 18 k | 17 k | 20 k | 141 k | 267 k | 239 k | 286 k | 329 k | 311 k | 400 k | 412 k | 454 k |
Pre tax profit | (29.9 m) | (29.4 m) | (30.6 m) | |||||||||
Income tax expense | (23 k) | (18 k) | (13 k) | |||||||||
Net Income | (13.7 m) | (16.4 m) | (19.7 m) | (26.1 m) | (32.7 m) | (30.4 m) | (27.1 m) | (30.2 m) | (25.4 m) | (29.9 m) | (29.4 m) | (30.6 m) |
- Source: SEC Filings
Balance Sheet
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 156 m | 150.6 m | 58.4 m | 49.7 m |
Inventories | 2 m | 2 m | 2 m | 2.1 m |
Current Assets | 158 m | 207.8 m | 177.6 m | 131.6 m |
PP&E | 240 k | 2.8 m | 3.5 m | 2.8 m |
Total Assets | 158.2 m | 220.3 m | 215.4 m | 180.4 m |
Accounts Payable | 1.7 m | 6.3 m | 3.8 m | 4.8 m |
Current Liabilities | 3.3 m | 12.3 m | 15.1 m | 16.5 m |
Total Liabilities | 18.1 m | |||
Additional Paid-in Capital | 217.5 m | 345.2 m | 455.2 m | 528.6 m |
Retained Earnings | (138.3 m) | (256.5 m) | (366.1 m) | |
Total Equity | 154.9 m | 206.8 m | 198.4 m | 162.2 m |
Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x |
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 144.9 m | 132.3 m | 227.1 m | 51.5 m | 24.2 m | 43.5 m | 42.2 m | 37.7 m | 43.9 m | 25.6 m | 55.4 m | 54.5 m |
Current Assets | 147.6 m | 135.3 m | 231.3 m | 249.3 m | 225.3 m | 198.3 m | 138.1 m | 124.2 m | 130.3 m | 112.2 m | 145.7 m | 121.7 m |
PP&E | 322 k | 604 k | 2.7 m | 3.3 m | 3.2 m | 3.7 m | 3.3 m | 3.2 m | 3 m | 2.7 m | 2.5 m | 2.3 m |
Total Assets | 149.3 m | 137.7 m | 235.2 m | 292 m | 263.3 m | 237 m | 192.1 m | 170.9 m | 183.6 m | 155.4 m | 185.8 m | 163.8 m |
Accounts Payable | 3.3 m | 3.5 m | 2.1 m | 7 m | 4.5 m | 4.6 m | 4.1 m | 4.1 m | 2.2 m | 4.2 m | 3.2 m | 1.9 m |
Current Liabilities | 5 m | 5.6 m | 6.2 m | 14.7 m | 14.1 m | 14.4 m | 13.2 m | 15.5 m | 15 m | 15.5 m | 17.5 m | 21.2 m |
Total Liabilities | 6 m | 7.4 m | 16.5 m | 16 m | 16.4 m | 15.1 m | 17.3 m | 16.7 m | 17.1 m | 19 m | 22.6 m | |
Additional Paid-in Capital | 220.4 m | 224.4 m | 340.2 m | 439.9 m | 444.6 m | 448.1 m | 460.5 m | 467.2 m | 506.1 m | 534.8 m | 592.5 m | 597.6 m |
Retained Earnings | (92.7 m) | (112.4 m) | (164.4 m) | (197.1 m) | (227.5 m) | (283.6 m) | (313.7 m) | (339.2 m) | (396.3 m) | (425.7 m) | (456.3 m) | |
Total Equity | 144.1 m | 131.7 m | 227.8 m | 275.5 m | 247.3 m | 220.6 m | 177 m | 153.6 m | 166.9 m | 138.4 m | 166.7 m | 141.2 m |
Financial Leverage | 1 x | 1 x | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.2 x |
Cash Flow
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (33.9 m) | (75.8 m) | (118.2 m) | (109.6 m) |
Depreciation and Amortization | 144 k | 323 k | 634 k | 717 k |
Inventories | (1.4 m) | (45 k) | (55 k) | (120 k) |
Accounts Payable | 664 k | 4.5 m | (2.4 m) | 945 k |
Cash From Operating Activities | (30.3 m) | (51.4 m) | (94 m) | (84.4 m) |
Purchases of PP&E | (57 k) | (2.8 m) | (1.4 m) | (70 k) |
Cash From Investing Activities | (57 k) | (67 m) | (90.8 m) | 24.6 m |
Cash From Financing Activities | 185.9 m | 113.1 m | 92.7 m | 51.2 m |
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (13.7 m) | (16.4 m) | (19.7 m) | (26.1 m) | (32.7 m) | (30.4 m) | (27.1 m) | (30.2 m) | (25.4 m) | (29.9 m) |
Accounts Payable | 3.5 m | 2.1 m | 7 m | 4.5 m | 4.6 m | 4.1 m | 4.1 m | 2.2 m | 4.2 m |
Report incorrect company information
